Two-Biomarker (IGHV mutational status and FISH cytogenetics) Prognostic Model Predicts Chronic Lymphocytic Leukemia Patient Outcome

This study evaluated a new system for determining the prognosis of patients with chronic lymphocytic leukemia (CLL; N=524) by looking at IGHV and FISH cytogenetics. Low-risk was defined as having mutated IGHV and no adverse FISH cytogenetics, intermediate risk as having either unmutated IGHV or adverse FISH cytogenetics, and high risk as having both. With this prognostic tool, low-, intermediate-, and high-risk CLL patients had 10-year overall survivals of 82%, 52%, and 27%, respectively.

https://www.ncbi.nlm.nih.gov/pubmed/?term=28120419